US › Healthcare

ATAI Life Sciences BV (ATAI)

US · Healthcare · Biotechnology

$7.180.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$953,999
Revenue YoY
-38.6%
Net profit
$-29.8M
Profit YoY
-12.7%
EPS
$-0.08
EPS estimate
$-0.10
Net margin
-3,121.8%

EPS came in at -0.08 against a street estimate of -0.10 — a beat of 17.8%.

Key statistics

Market cap
$2.66B
Forward P/E
0.0
P/B
13.37
Book value
$0.54
EPS (TTM)
$-2.84
52-week high
$7.22
52-week low
$3.27
50-day MA
$5.18
200-day MA
$4.41
Beta
1.57

Analyst view

Analysts rate ATAI Life Sciences BV a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $9.59.

Shareholding

Insiders
2.34%
Institutions
44.80%

Largest institutional holders

FundStake
Deep Track Capital, LP3.24%
Vanguard Capital Management, LLC3.18%
UBS Group AG2.01%
BlackRock Inc1.85%
Adage Capital Partners Gp LLC1.53%
Susquehanna International Group, LLP1.43%
Millennium Management LLC1.18%
Morgan Stanley - Brokerage Accounts1.04%

Recent filings & reports

DocumentDate
Material agreement · Q3 20262026-07-16
Shareholder vote results · Q2 20262026-06-08
Reg FD disclosure · Q2 20262026-06-03
Quarterly report · Q1 20262026-05-12
Results announced · Q2 20262026-05-12
Proxy statement · Q2 20262026-04-22
Annual report FY20252026-03-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ATAI Life Sciences BV — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.